{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:39:06Z","timestamp":1793947146980,"version":"4.8.0"},"reference-count":143,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.survophthal.2012.01.007","type":"journal-article","created":{"date-parts":[[2012,8,13]],"date-time":"2012-08-13T15:36:28Z","timestamp":1344872188000},"page":"415-429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":344,"title":["Corneal Neovascularization: An Anti-VEGF Therapy Review"],"prefix":"10.1016","volume":"57","author":[{"given":"Jin-Hong","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin K.","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Lunde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu-Yeon","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri T.","family":"Azar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.survophthal.2012.01.007_bib1","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1442-9071.2009.02112.x","article-title":"Effect of bevacizumab on corneal neovascularization in experimental rabbit model","volume":"37","author":"Ahmed","year":"2009","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib2","first-page":"18","article-title":"Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization","volume":"39","author":"Amano","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2012.01.007_bib3","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nature05249","article-title":"Corneal avascularity is due to soluble VEGF receptor-1","volume":"443","author":"Ambati","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.survophthal.2012.01.007_bib4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2012.01.007_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/IAE.0b013e31822528fc","article-title":"Three-year safety and visual acuity results of epimacular 90strontium\/90yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration","volume":"32","author":"Avila","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2012.01.007_bib6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3109\/02713680903429007","article-title":"Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model","volume":"35","author":"Avisar","year":"2010","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.survophthal.2012.01.007_bib7","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.jcrs.2007.07.012","article-title":"Subconjunctival bevacizumab for vascularized rejected corneal grafts","volume":"33","author":"Awadein","year":"2007","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.survophthal.2012.01.007_bib8","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.ophtha.2010.01.039","article-title":"Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis","volume":"117","author":"Bachmann","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.01.007_bib9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archopht.126.1.71","article-title":"Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation","volume":"126","author":"Bachmann","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/bjo.2008.145128","article-title":"Transient postoperative vascular endothelial growth factor (VEGF)\u2013neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation","volume":"93","author":"Bachmann","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.molmed.2010.01.004","article-title":"Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale","volume":"16","author":"Bagri","year":"2010","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.survophthal.2012.01.007_bib12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization","volume":"27","author":"Bahar","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2012.01.007_bib13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/02713680701799101","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium","volume":"33","author":"Bahar","year":"2008","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.survophthal.2012.01.007_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/jop.2010.0094","article-title":"Bevacizumab and ocular wound healing after primary pterygium excision","volume":"27","author":"Banifatemi","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.survophthal.2012.01.007_bib15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3109\/09273948.2010.490630","article-title":"Severe corneal changes following intravitreal injection of bevacizumab","volume":"18","author":"Bayar","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"10.1016\/j.survophthal.2012.01.007_bib16","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jfo.2011.03.004","article-title":"[Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration]","volume":"34","author":"Bidot","year":"2011","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.exer.2005.05.001","article-title":"Involvement of IL-6 in the paracrine production of VEGF in ocular HSV-1 infection","volume":"82","author":"Biswas","year":"2006","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.survophthal.2012.01.007_bib18","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00347-007-1512-2","article-title":"[Inhibition of angiogenesis in the anterior chamber of the eye]","volume":"104","author":"Bock","year":"2007","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.survophthal.2012.01.007_bib19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","article-title":"Bevacizumab (Avastin) eye drops inhibit corneal neovascularization","volume":"246","author":"Bock","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib20","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.ophtha.2011.02.039","article-title":"Primary endpoint results of a phase ii study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.01.007_bib21","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/01.ico.0000611440.32234.8f","article-title":"Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis","volume":"27","author":"Carrasco","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2012.01.007_bib22","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/ICO.0b013e31818b8be0","article-title":"Evaluation of cytotoxic effects of bevacizumab on human corneal cells","volume":"28","author":"Chalam","year":"2009","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2012.01.007_bib23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2012.01.007_bib24","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00417-011-1709-6","article-title":"Combination of vascular endothelial growth factor receptor\/platelet\u2013derived growth factor receptor inhibition markedly improves the antiangiogenic efficacy for advanced stage mouse corneal neovascularization","volume":"249","author":"Chaoran","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/ICO.0b013e3181e458c5","article-title":"Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition","volume":"30","author":"Chu","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2012.01.007_bib26","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1167\/iovs.03-1380","article-title":"Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival","volume":"45","author":"Cursiefen","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2012.01.007_bib27","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1172\/JCI20465","article-title":"VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment","volume":"113","author":"Cursiefen","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.survophthal.2012.01.007_bib28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00003226-200304000-00021","article-title":"Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology","volume":"22","author":"Cursiefen","year":"2003","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2012.01.007_bib29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bjo.87.1.101","article-title":"Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation","volume":"87","author":"Cursiefen","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib30","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":"Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib31","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1167\/iovs.09-3745","article-title":"Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival","volume":"51","author":"Dastjerdi","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2012.01.007_bib32","doi-asserted-by":"crossref","first-page":"8718","DOI":"10.1167\/iovs.11-7871","article-title":"Corneal penetration of topical and subconjunctival bevacizumab","volume":"52","author":"Dastjerdi","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2012.01.007_bib33","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1167\/iovs.05-1071","article-title":"The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization","volume":"47","author":"Dell","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2012.01.007_bib34","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jcrs.2010.12.037","article-title":"Anatomy and physiology of the cornea","volume":"37","author":"DelMonte","year":"2011","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.survophthal.2012.01.007_bib35","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archopht.125.6.834","article-title":"Topical bevacizumab therapy for corneal neovascularization","volume":"125","author":"DeStafeno","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib36","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1517\/13543780903201684","article-title":"VEGF trap-eye for the treatment of neovascular age-related macular degeneration","volume":"18","author":"Dixon","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.survophthal.2012.01.007_bib37","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/bjo.2008.138271","article-title":"An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor trap-eye in patients with diabetic macular oedema","volume":"93","author":"Do","year":"2009","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2012.01.007_bib38","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.ophtha.2011.02.018","article-title":"The DA VINCI Study: Phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema","volume":"118","author":"Do","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.01.007_bib39","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e31817786ad","article-title":"Subconjunctival bevacizumab for corneal neovascularization","volume":"27","author":"Doctor","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2012.01.007_bib40","first-page":"2326","article-title":"Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization","volume":"15","author":"Dratviman-Storobinsky","year":"2009","journal-title":"Mol Vis"},{"key":"10.1016\/j.survophthal.2012.01.007_bib41","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrm1129","article-title":"Killing the messenger: short RNAs that silence gene expression","volume":"4","author":"Dykxhoorn","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib42","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.preteyeres.2010.01.002","article-title":"Novel aspects of corneal angiogenic and lymphangiogenic privilege","volume":"29","author":"Ellenberg","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.survophthal.2012.01.007_bib43","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","article-title":"Subconjunctival bevacizumab for corneal neovascularization","volume":"245","author":"Erdurmus","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/02713680903395273","article-title":"Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium","volume":"35","author":"Fallah","year":"2010","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.survophthal.2012.01.007_bib45","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.addr.2006.07.020","article-title":"Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA","volume":"58","author":"Fattal","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.survophthal.2012.01.007_bib46","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.survophthal.2012.01.007_bib47","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.survophthal.2012.01.007_bib48","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.survophthal.2012.01.007_bib49","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2012.01.007_bib50","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","article-title":"The International Intravitreal Bevacizumab Safety Survey: using the Internet to assess drug safety worldwide","volume":"90","author":"Fung","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib51","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4103\/0301-4738.30702","article-title":"Evaluation of 19 cases of inadvertent globe perforation due to periocular injections","volume":"55","author":"Gadkari","year":"2007","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib52","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/ICO.0b013e318180e50f","article-title":"Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery","volume":"27","author":"Gerten","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2012.01.007_bib53","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2012.01.007_bib54","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jfo.2010.07.007","article-title":"[Subconjunctival bevacizumab for corneal neovascularization]","volume":"33","author":"Gueudry","year":"2010","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib55","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1755-3768.2009.01571.x","article-title":"The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization","volume":"88","author":"Habot-Wilner","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib56","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000322061","article-title":"Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats","volume":"46","author":"Hashemian","year":"2011","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.survophthal.2012.01.007_bib57","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000224783","article-title":"Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats","volume":"42","author":"Hashemian","year":"2009","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.survophthal.2012.01.007_bib58","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/ICO.0b013e3181e291a6","article-title":"Deep intrastromal bevacizumab injection for management of corneal stromal vascularization after deep anterior lamellar keratoplasty, a novel technique","volume":"30","author":"Hashemian","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2012.01.007_bib59","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3109\/02713683.2010.513797","article-title":"The induction of an angiogenic response in corneal myofibroblasts by platelet-activating factor (PAF)","volume":"35","author":"He","year":"2010","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.survophthal.2012.01.007_bib60","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.ophtha.2011.03.020","article-title":"The 1-year results of CLEAR\u2013IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing","volume":"118","author":"Heier","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.01.007_bib61","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1442-9071.2010.02252.x","article-title":"Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone","volume":"38","author":"Hoffart","year":"2010","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib62","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.survophthal.2012.01.007_bib63","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1167\/iovs.07-1314","article-title":"Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation","volume":"49","author":"Hos","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2012.01.007_bib64","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.mehy.2007.01.032","article-title":"Therapeutic potential of bevacizumab (Avastin) in herpetic stromal keratitis (HSK)","volume":"69","author":"Hosseini","year":"2007","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.survophthal.2012.01.007_bib65","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.mehy.2006.06.063","article-title":"A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents","volume":"68","author":"Hosseini","year":"2007","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.survophthal.2012.01.007_bib66","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.mehy.2007.01.047","article-title":"Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia","volume":"69","author":"Hosseini","year":"2007","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.survophthal.2012.01.007_bib67","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1442-9071.2007.01572.x","article-title":"Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis","volume":"35","author":"Hosseini","year":"2007","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib68","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2012.01.007_bib69","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncponc0403","article-title":"Lessons from phase III clinical trials on anti-VEGF therapy for cancer","volume":"3","author":"Jain","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib70","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2353\/ajpath.2006.050588","article-title":"Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization","volume":"168","author":"Jo","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib71","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ajo.2010.02.006","article-title":"RNA-based treatment for neovascular age-related macular degeneration by Sirna-027","volume":"150","author":"Kaiser","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib72","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1023\/A:1006486207583","article-title":"Electrocardiographic changes during subconjunctival injections","volume":"23","author":"Kayikcioglu","year":"1999","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib73","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrc905","article-title":"Clinical translation of angiogenesis inhibitors","volume":"2","author":"Kerbel","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.survophthal.2012.01.007_bib74","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.arcmed.2008.10.004","article-title":"Inhibition of corneal neovascularization with propolis extract","volume":"40","author":"Keshavarz","year":"2009","journal-title":"Arch Med Res"},{"key":"10.1016\/j.survophthal.2012.01.007_bib75","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/S0002-9440(10)63267-1","article-title":"Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis","volume":"165","author":"Kim","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib76","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.01.007_bib77","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1167\/iovs.08-2805","article-title":"Bevacizumab application delays epithelial healing in rabbit cornea","volume":"50","author":"Kim","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2012.01.007_bib78","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/ICO.0b013e31815cf67d","article-title":"Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin)","volume":"27","author":"Kim","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2012.01.007_bib79","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2174\/138955709788922665","article-title":"Treating age-related macular degeneration\u2014interaction of VEGF-antagonists with their target","volume":"9","author":"Klettner","year":"2009","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.survophthal.2012.01.007_bib80","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","article-title":"Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization","volume":"247","author":"Koenig","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib81","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1755-3768.2008.01312.x","article-title":"Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration","volume":"87","author":"Krebs","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib82","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0039-6257(98)00035-6","article-title":"Ocular neovascularization: an epidemiologic review","volume":"43","author":"Lee","year":"1998","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib83","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1172\/JCI0215755","article-title":"Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus","volume":"110","author":"Lee","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.survophthal.2012.01.007_bib84","doi-asserted-by":"crossref","first-page":"800","DOI":"10.5483\/BMBRep.2009.42.12.800","article-title":"Bevacizumab accelerates corneal wound healing by inhibiting TGF-beta2 expression in alkali-burned mouse cornea","volume":"42","author":"Lee","year":"2009","journal-title":"BMB Rep"},{"key":"10.1016\/j.survophthal.2012.01.007_bib85","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1167\/iovs.09-4571","article-title":"The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency","volume":"51","author":"Lin","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2012.01.007_bib86","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00280-010-1457-z","article-title":"Suramab, a novel antiangiogenic agent, reduces tumor growth and corneal neovascularization","volume":"67","author":"Lopez","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib87","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1001\/archopht.1991.01080070100045","article-title":"Immunohistochemistry of Terrien's and Mooren's corneal degeneration","volume":"109","author":"Lopez","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib88","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1128\/jvi.68.1.84-92.1994","article-title":"Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus","volume":"68","author":"Lyttle","year":"1994","journal-title":"J Virol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib89","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1167\/iovs.04-0128","article-title":"Platelet-activating factor (PAF) induces corneal neovascularization and upregulates VEGF expression in endothelial cells","volume":"45","author":"Ma","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2012.01.007_bib90","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0161-6420(94)31138-9","article-title":"Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group","volume":"101","author":"Maguire","year":"1994","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.01.007_bib91","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/ICO.0b013e3181d927b9","article-title":"The effect of subconjunctival ranibizumab on primary pterygium: a pilot study","volume":"29","author":"Mandalos","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2012.01.007_bib92","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":"Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib93","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-relatedmacular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2012.01.007_bib94","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/08820530902801106","article-title":"Pterygia: pathogenesis and the role of subconjunctival bevacizumab in treatment","volume":"24","author":"Mauro","year":"2009","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib95","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/02713680500514636","article-title":"Inhibition of ocular angiogenesis by diced small interfering RNAs (siRNAs) specific to vascular endothelial growth factor (VEGF)","volume":"31","author":"Murata","year":"2006","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.survophthal.2012.01.007_bib96","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/ICO.0b013e31817780b6","article-title":"Genetic ablation of CD36 induces age-related corneal neovascularization","volume":"27","author":"Mwaikambo","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2012.01.007_bib97","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2174\/187153008786848330","article-title":"Emerging roles for the CD36 scavenger receptor as a potential therapeutic target for corneal neovascularization","volume":"8","author":"Mwaikambo","year":"2008","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.survophthal.2012.01.007_bib98","doi-asserted-by":"crossref","first-page":"462","DOI":"10.2174\/156800910791517208","article-title":"Tyrosine kinase inhibitors","volume":"10","author":"Natoli","year":"2010","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.survophthal.2012.01.007_bib99","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.ophtha.2009.04.030","article-title":"A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration","volume":"116","author":"Nguyen","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.01.007_bib100","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.ophtha.2006.05.055","article-title":"A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration","volume":"113","author":"Nguyen","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2012.01.007_bib101","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1167\/iovs.08-3148","article-title":"Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits","volume":"50","author":"Nomoto","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2012.01.007_bib102","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/02713680802607740","article-title":"The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas","volume":"34","author":"Oh","year":"2009","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.survophthal.2012.01.007_bib103","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/ICO.0b013e31819839f9","article-title":"Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy","volume":"28","author":"Oh","year":"2009","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2012.01.007_bib104","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/112067211002000106","article-title":"VEGF trap(R1R2) suppresses experimental corneal angiogenesis","volume":"20","author":"Oliveira","year":"2010","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib105","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ajo.2007.11.003","article-title":"Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model","volume":"145","author":"Papathanassiou","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib106","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ajo.2010.04.024","article-title":"Inhibition of corneal neovascularization by topical bevacizumab (anti-VEGF) and Sunitinib (anti-VEGF and anti-PDGF) in an animal model","volume":"150","author":"Perez-Santonja","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib107","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/eye.2008.88","article-title":"Anti-VEGF therapy: comparison of current and future agents","volume":"22","author":"Pieramici","year":"2008","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2012.01.007_bib108","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/ICO.0b013e31817c41e3","article-title":"Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization","volume":"27","author":"Qian","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2012.01.007_bib109","first-page":"104","article-title":"Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes","volume":"17","author":"Rocher","year":"2011","journal-title":"Mol Vis"},{"key":"10.1016\/j.survophthal.2012.01.007_bib110","first-page":"361","article-title":"Ranibizumab: phase III clinical trial results","volume":"19","author":"Rosenfeld","year":"2006","journal-title":"Ophthalmol Clin North Am"},{"key":"10.1016\/j.survophthal.2012.01.007_bib111","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbrc.2007.02.156","article-title":"Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor","volume":"356","author":"Roskoski","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.survophthal.2012.01.007_bib112","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00417-009-1101-y","article-title":"Anti-VEGF monoclonal antibody\u2013induced regression of corneal neovascularization and inflammation in a rabbit model of herpetic stromal keratitis","volume":"247","author":"Saravia","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib113","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1177\/112067210901900530","article-title":"Topical bevacizumab for corneal neovascularization after penetrating keratoplasty","volume":"19","author":"Saxena","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib114","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1517\/17425247.3.3.445","article-title":"ICS\u2013283: a system for targeted intravenous delivery of siRNA","volume":"3","author":"Schiffelers","year":"2006","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.survophthal.2012.01.007_bib115","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2174\/187221309789257450","article-title":"Corneal neovascularization: molecular events and therapeutic options","volume":"3","author":"Shakiba","year":"2009","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"10.1016\/j.survophthal.2012.01.007_bib116","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.arcmed.2007.04.006","article-title":"Inhibition of corneal neovascularization with a nutrient mixture containing lysine, proline, ascorbic acid, and green tea extract","volume":"38","author":"Shakiba","year":"2007","journal-title":"Arch Med Res"},{"key":"10.1016\/j.survophthal.2012.01.007_bib117","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0420.2007.01067.x","article-title":"Complications in patients after intravitreal injection of bevacizumab","volume":"86","author":"Shima","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib118","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1136\/bjo.2007.132597","article-title":"Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial","volume":"92","author":"Singerman","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib119","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/ICO.0b013e31802b4201","article-title":"Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization","volume":"26","author":"Singh","year":"2007","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2012.01.007_bib120","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.bbrc.2003.11.057","article-title":"Cationic liposome\u2013mediated delivery of siRNAs in adult mice","volume":"312","author":"Sioud","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.survophthal.2012.01.007_bib121","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/01.iae.0000238561.99283.0e","article-title":"Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2012.01.007_bib122","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/bjo.2007.134874","article-title":"Predicted biological activity of intravitreal VEGF Trap","volume":"92","author":"Stewart","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib123","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/nri1224","article-title":"Ocular immune privilege: therapeutic opportunities from an experiment of nature","volume":"3","author":"Streilein","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib124","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/ICO.0b013e3181ba0ae2","article-title":"Corneal graft surgery combined with subconjunctival bevacizumab (Avastin)","volume":"29","author":"Symes","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2012.01.007_bib125","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/jop.2006.22.213","article-title":"A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in\u00a0vivo","volume":"22","author":"Takahashi","year":"2006","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.survophthal.2012.01.007_bib126","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","article-title":"Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease","volume":"56","author":"Tolentino","year":"2011","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2012.01.007_bib127","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/ICO.0b013e31821dd986","article-title":"Hemangiogenesis and lymphangiogenesis in corneal pathology","volume":"31","author":"Tshionyi","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2012.01.007_bib128","doi-asserted-by":"crossref","first-page":"c2459","DOI":"10.1136\/bmj.c2459","article-title":"Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study","volume":"340","author":"Tufail","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.survophthal.2012.01.007_bib129","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/ICO.0b013e318158f6ad","article-title":"Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome","volume":"27","author":"Uy","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2012.01.007_bib130","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00417-009-1170-y","article-title":"Avastin use in high risk corneal transplantation","volume":"247","author":"Vassileva","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib131","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1442-9071.1987.tb00300.x","article-title":"Hierarchy of prognostic factors for corneal allograft survival","volume":"15","author":"Volker-Dieben","year":"1987","journal-title":"Aust NZ J Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib132","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.colsurfb.2007.06.013","article-title":"The expression patterns of vascular endothelial growth factor and thrombospondin 2 after corneal alkali burn","volume":"60","author":"Yan","year":"2007","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.survophthal.2012.01.007_bib133","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1097\/00007890-199812150-00016","article-title":"Effect of a topically applied neutralizing antibody against vascular endothelial growth factor on corneal allograft rejection of rat","volume":"66","author":"Yatoh","year":"1998","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.survophthal.2012.01.007_bib134","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/ICO.0b013e31821379aa","article-title":"Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization","volume":"30","author":"Yeung","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2012.01.007_bib135","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/ICO.0b013e3180de1d0a","article-title":"Safety profile of bevacizumab on cultured human corneal cells","volume":"26","author":"Yoeruek","year":"2007","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2012.01.007_bib136","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0420.2007.01049.x","article-title":"Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn","volume":"86","author":"Yoeruek","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib137","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/sj.gt.3302442","article-title":"Lipid-mediated delivery of brain-specific angiogenesis inhibitor 1 gene reduces corneal neovascularization in an in\u00a0vivo rabbit model","volume":"12","author":"Yoon","year":"2005","journal-title":"Gene Ther"},{"key":"10.1016\/j.survophthal.2012.01.007_bib138","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/ICO.0b013e3181dc81a0","article-title":"Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization","volume":"30","author":"You","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2012.01.007_bib139","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1755-3768.2008.01399.x","article-title":"Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization","volume":"87","author":"You","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib140","first-page":"1988","article-title":"Corneal neovascularization during experimental fungal keratitis","volume":"15","author":"Yuan","year":"2009","journal-title":"Mol Vis"},{"key":"10.1016\/j.survophthal.2012.01.007_bib141","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1755-3768.2009.01585.x","article-title":"Subconjunctival bevacizumab for corneal neovascularization","volume":"88","author":"Zaki","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib142","doi-asserted-by":"crossref","first-page":"9828","DOI":"10.1128\/JVI.75.20.9828-9835.2001","article-title":"Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis","volume":"75","author":"Zheng","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.survophthal.2012.01.007_bib143","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/02713681003597230","article-title":"A siRNA targeting vascular endothelial growth factor-A inhibiting experimental corneal neovascularization","volume":"35","author":"Zuo","year":"2010","journal-title":"Curr Eye Res"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625712000100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625712000100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:38:37Z","timestamp":1758541117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625712000100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":143,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0039625712000100"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2012.01.007","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Corneal Neovascularization: An Anti-VEGF Therapy Review","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2012.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}